Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis.

ABSTRACT:

Background

Bone mesenchymal stem cells (MSCs) can promote liver regeneration and inhibit inflammation and hepatic fibrosis. MSCs also can serve as a vehicle for gene therapy. Smad7 is an essential negative regulatory gene in the TGF-β1/Smad signalling pathway. Activation of TGF-β1/Smad signalling accelerates liver inflammation and fibrosis; we therefore hypothesized that MSCs overexpressing the Smad7 gene might be a new cell therapy approach for treating liver fibrosis via the inhibition of TGF-β1/Smad signalling.

Methods

MSCs were isolated from 6-week-old Wistar rats and transduced with the Smad7 gene using a lentivirus vector. Liver cirrhosis was induced by subcutaneous injection of carbon tetrachloride (CCl₄) for 8 weeks. The rats with established liver cirrhos

SUBMITTER: Su DN 

PROVIDER: S-EPMC7489041 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature